Shorts

1:12
FDA testosterone label updates: 2 meaningful changes
a month ago
by
Helen L. Bernie, DO, MPH

0:36
EV-302 response rates put surgical consolidation in context
2 months ago
by
Betty Wang, MD

0:52
Amy E. Krambeck, MD, outlines anatomic enucleation course
2 months ago
by
Amy E. Krambeck, MD

1:23
Daniel J. George, MD, on the significance of capivasertib for PTEN-deficient mHSPC
2 months ago
by
Daniel J. George, MD

1:43
What it takes to move the needle on urologic patient safety
2 months ago
by
Matthew Nielsen, MD, MS, FACS

0:42
Why patients choose Break Wave over URS
2 months ago
by
Ben H. Chew, MD, MSc

0:36
Jenny N. Guo, MD, on key BPH takeaways from AUA 2026
2 months ago
by
Jenny N. Guo, MD

0:44
Joy Maulik, CRNP, highlights LUGPA Advanced Practice Provider Forum
2 months ago
by
Joy Maulik, CRNP

1:02
The UroOnc Minute: Patient selection for MDT in the PSMA-PET era
2 months ago
by
Adam B. Weiner, MD(+1 more)

0:55
Archan Khandekar, MD, on the future for AI in urology
2 months ago
by
Archan Khandekar, MD

0:45
Praful Ravi, MB, BChir, MRCP, on residual disease detection using PSMA-PET
2 months ago
by
Praful Ravi, MB, BChir, MRCP

0:28
What BULLSEYE's PFS data should—and shouldn't—mean
2 months ago
by
James Nagarajah, MD

0:28
Why Break Wave Lithotripsy is a game changer for stone care
2 months ago
by
Ben H. Chew, MD, MSc

0:40
Aleece Fosnight, MSPAS, PA-C, on what to tell patients about microplastics and bladder health
2 months ago
by
Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, IF, MSCP, HAES

0:47
Louise Emmett, MD, PhD, MBChB, FRACP, on the potential role of 225Ac-PSMA-617 earlier in mCRPC
2 months ago

0:35
Lucia Nappi, MD, on the future for miR371 in testicular cancer
2 months ago
by
Lucia Nappi, MD, PhD, FRCPC

0:42
Joshua Lang, MD, MS, highlights emerging biomarker strategies in GU oncology
2 months ago
by
Joshua Lang, MD, MS

1:24
Integrating immunotherapy into newly diagnosed MIBC
2 months ago
by
María Natalia Gandur Quiroga, MD, MSc

0:33
Kari A.O. Tikkinen, MD, PhD, discusses tranexamic acid in urology
2 months ago
by
Kari A.O. Tikkinen, MD, PhD

1:38
Nicole L. Miller, MD, FACS, on advances in evaluating and treating LUTS
2 months ago
by
Nicole L. Miller, MD, FACS

0:32
Catherine A. Matthews, MD, FACS, shares takeaways from the INTIBIA Pivotal Trial
2 months ago
by
Catherine A. Matthews, MD, FACOG, FACS, FPMRS

0:22
Michael S. Cookson, MD, on darolutamide’s safety profile
3 months ago
by
Michael S. Cookson, MD, MMHC, FACS

0:41
Jonathan D. Harper, MD, on increasing fluid intake to prevent recurrent stones
3 months ago
by
Jonathan D. Harper, MD

0:57
Nima Almassi, MD, on shared decision-making around bladder-preserving treatment options
3 months ago
by
Nima Almassi, MD

0:49
Kathryn H. Gessner, MD, PhD, on the most exciting current developments in bladder cancer
3 months ago
by
Kate Gessner, MD, PhD

0:18
Joshua J. Meeks, MD, PhD, on the need for recombinant BCG
3 months ago
by
Joshua J. Meeks, MD, PhD

0:39
Nicole L. Miller, MD, FACS, on what she tells patients after BPH treatment failure
3 months ago
by
Nicole L. Miller, MD, FACS

0:30
Michael S. Cookson, MD, on what ARASEC adds to the treatment intensification discussion
3 months ago
by
Michael S. Cookson, MD, MMHC, FACS

0:22
Catherine A. Matthews, MD, FACS, on the U-POP & LUTD 2026 Global Consensus Conference
3 months ago
by
Catherine A. Matthews, MD, FACOG, FACS, FPMRS

0:20
Hung-Jui (Ray) Tan, MD, MSHPM, on how urology can close the workforce gap in underserved areas
3 months ago
by
Hung-Jui (Ray) Tan, MD, MSHPM
Advertisement
Advertisement
Trending on Urology Times
1
Trial to evaluate ivonescimab plus enfortumab vedotin in urothelial carcinoma
2
FDA clears Revi Extend implant for urgency urinary incontinence
3
Neil Baum, MD, and Abraham Morgentaler, MD, discuss the history of testosterone and prostate cancer
4
Alan Bryce, MD, highlights key phase 3 advances in prostate cancer
5
